Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

Area of Science:

• Molecular Biology
• Cancer Research
• Immunology

Background:

• Nuclear factor kappaB (NF-kappaB) transcription factors regulate critical physiological processes including immune responses, cell proliferation, and inflammation.
• Aberrant regulation of NF-kappaB signaling pathways is implicated in the development, progression, and treatment resistance of various cancers.
• Multiple myeloma serves as a key example where NF-kappaB involvement is increasingly evident.

Purpose of the Study:

• To review recent evidence linking NF-kappaB to human cancer, with a focus on multiple myeloma.
• To explore the therapeutic potential and benefits of targeting NF-kappaB in cancer treatment.
• To discuss potential complications and challenges associated with NF-kappaB-targeted therapies.

Main Methods:

• Review of recent findings from cancer genetics studies.
• Analysis of cancer genome data.
• Synthesis of evidence on NF-kappaB pathway dysregulation in human cancers.
• Evaluation of therapeutic strategies targeting NF-kappaB.

Main Results:

• Cancer genetics and genome studies provide strong support for NF-kappaB's role in human cancer.
• NF-kappaB dysregulation is a significant factor in multiple myeloma pathogenesis.
• Targeting NF-kappaB presents a promising therapeutic avenue for cancer treatment.
• Potential pitfalls and complications of NF-kappaB-targeted therapies are identified.

Conclusions:

• NF-kappaB transcription factors are integral to cellular processes, and their aberrant activity drives cancer development and progression.
• Evidence from cancer genetics strongly implicates NF-kappaB in human malignancies, notably multiple myeloma.
• Targeting NF-kappaB offers significant therapeutic potential for cancer, but careful consideration of associated complications is necessary.